A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza) in Intermediate-2 and High Risk MDS Patients.

Trial Profile

A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza) in Intermediate-2 and High Risk MDS Patients.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 28 Oct 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 15 Mar 2013 Planned End Date changed from 1 Jan 2014 to 1 Jan 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top